Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies

17 Mar, 2021

Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies
Photo by Kelly Sikkema on Unsplash

– Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the close of an oversubscribed $150 million Series B financing.
– The company will use the funds to expand and advance into the clinic its pipeline of investigational high efficiency, targeted gene integration therapies with curative potential for serious diseases.
RA Capital Management and Rock Springs Capital led the financing with significant participation from new investors Cormorant Asset Management, Deerfield Management Company, Federated Hermes Kaufmann Funds, Fidelity Management & Research Company, Janus Henderson Investors, Logos Capital, OrbiMed, Perceptive Advisors, Surveyor Capital (a Citadel company), and Venrock Healthcare Capital Partners, joining existing investor Samsara BioCapital and founding investor Versant Ventures.

Biotechnology North America
Crunchbase icon

Content report

The following text will be sent to our editors: